RecruitingNCT07012759
Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients
Novel Pleural Effusion Biomarkers Screening and Evaluation in Lung Adenocarcinoma Patients
Sponsor
Fu Jen Catholic University
Enrollment
100 participants
Start Date
Jun 10, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need.
- Signed informed consent.
Exclusion Criteria2
- Patients under the age of 18.
- Patients with malignancies other than lung adenocarcinoma.
Interventions
OTHERbiomarkers
pleural effusion biomarkers in lung adenocarcinoma
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07012759
Related Trials
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
NCT0519883034 locations
Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma.
NCT074790951 location
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
Engagement of Veterans With Lung Cancer
NCT072192511 location
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT0579716860 locations